ArticleSurgical case reports2025
Successful Use of Extracorporeal LVAD for Cardiogenic Shock with Aortic Valve Regurgitation as Bridge to Surgery.
Article in Surgical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIntra-aortic balloon pumping (IABP), Impella, and veno-arterial extracorporeal membrane oxygenation (VA-ECMO) are common percutaneous devices used to manage hemodynamic instability in patients with cardiogenic shock. These devices play a critical role in providing circulatory support. However, they may fail to achieve sufficient left ventricular unloading in patients with aortic valve regurgitation (AR), potentially complicating treatment strategies. In such challenging cases, an extracorporeal left ventricular assist device (LVAD) may serve as an effective alternative solution. CASE PRESENTATION: A 61-year-old man presented with heart failure and cardiogenic shock, further complicated by AR. Despite intensive inotropic therapy, his condition deteriorated, leading to significant hepatic and renal dysfunction. Echocardiography revealed left ventricular dysfunction with an ejection fraction of 23.5%, as well as moderate aortic, mitral, and tricuspid valve regurgitation. Initial management with VA-ECMO proved inadequate, necessitating the implantation of an extracorporeal LVAD. This intervention resulted in marked improvements in hemodynamics and multi-organ function. Subsequently, the patient underwent successful surgical procedures, including aortic valve replacement, mitral and tricuspid annuloplasty, and pulmonary vein isolation. He was discharged on day 51.
conclusionsThis case highlights the challenges in managing cardiogenic shock with AR, where conventional devices like IABP, Impella, and VA-ECMO may exacerbate the condition. The use of an extracorporeal LVAD provided effective left ventricular unloading, enabling successful preoperative optimization and surgery. This case supports the utility of LVAD as a bridge to surgery in patients with cardiogenic shock and AR, suggesting a need for further research into optimal management strategies in such complex cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.